Korea's AriBio Progresses Phase III Program For Oral Alzheimer's Contender
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.
You may also be interested in...
Plus deals involving SK pharmteco/CBM, Kezar/Everest, Cerecin/University of Alberta, PeptiDream/Genentech, Aclipse/Chong Kun Dang and Cure Genetics/Frametact.
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.